Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system.
about
Insights into Newer Antimicrobial Agents Against Gram-negative BacteriaTreatment Options for Carbapenem-Resistant Enterobacteriaceae InfectionsComparable Efficacy of Tigecycline versus Colistin Therapy for Multidrug-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Pneumonia in Critically Ill PatientsThe global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignanciesRisk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort studyResistance to Colistin in Klebsiella Pneumoniae: A 4.0 Strain?Convulsions in a critically ill patient on hemodialysis: Possible role of low dose colistinCarbapenem-resistant Enterobacteriaceae: a review of treatment and outcomesCarbapenem-resistant Enterobacteriaceae: a menace to our most vulnerable patientsCarbapenem-resistant Enterobacteriaceae: biology, epidemiology, and management.Validation of a model to predict the risk of nephrotoxicity in patients receiving colistinTrough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study.High dose intravenous colistin methanesulfonate therapy is associated with high rates of nephrotoxicity; a prospective cohort study from Saudi ArabiaComplex prosthetic joint infections due to carbapenemase-producing Klebsiella pneumoniae: a unique challenge in the era of untreatable infections.The use of intravenous colistin among children in the United States: results from a multicenter, case seriesPreliminary clinical study of the effect of ascorbic acid on colistin-associated nephrotoxicityCarbapenem-resistant and carbapenem-susceptible isogenic isolates of Klebsiella pneumoniae ST101 causing infection in a tertiary hospital.Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patientsPolymyxin B Nephrotoxicity: From Organ to Cell Damage.In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa.Molecular epidemiology of carbapenem resistant gram-negative bacilli from infected pediatric population in tertiary - care hospitals in Medellín, Colombia: an increasing problem.Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial killCharacterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen designColistin Population Pharmacokinetics after Application of a Loading Dose of 9 MU Colistin Methanesulfonate in Critically Ill Patients.Defining the incidence and risk factors of colistin-induced acute kidney injury by KDIGO criteriaMultidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches.Paradoxical Effect of Polymyxin B: High Drug Exposure Amplifies Resistance in Acinetobacter baumanniiHow does colistin-induced nephropathy develop and can it be treated?Evaluation of Risk Factors for Intravenous Colistin Use-related NephrotoxicityIn Vitro Synergistic Activity of Antimicrobial Agents in Combination against Clinical Isolates of Colistin-Resistant Acinetobacter baumannii.Combinatorial pharmacodynamics of polymyxin B and tigecycline against heteroresistant Acinetobacter baumannii.In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy.Treatment of complicated urinary tract infections with an emphasis on drug-resistant gram-negative uropathogens.Carbapenem-resistant Acinetobacter baumannii: epidemiology, surveillance and management.Emergent renal dysfunction with colistin pharmacotherapy.Pharmacotherapy for hospital-acquired pneumonia.Combination therapy in severe Acinetobacter baumannii infections: an update on the evidence to date.Colistin: understanding and applying recent pharmacokinetic advances.Impact of hospital guideline for weight-based antimicrobial dosing in morbidly obese adults and comprehensive literature review.Colistin- and polymyxin-induced nephrotoxicity: focus on literature utilizing the RIFLE classification scheme of acute kidney injury.
P2860
Q26751255-1654ECC3-6EC6-40E2-BC58-E23BB38CA5E2Q28082546-3812E5CA-F0E1-4862-96F7-BE147A546491Q28550492-50D29290-D85A-4FD6-BFFF-23AE8A8C6420Q33686940-14FC6976-7D83-4907-BDF8-C54D7968D562Q33751736-0059B541-0675-4EB4-A99C-05A7489631EAQ33803459-04F1AFDF-13EA-4DED-9CED-55289767ACCAQ34124176-B2CE9B80-7051-4AE5-97DD-89C14EFD681BQ34320945-366734A1-E09F-4B7B-B218-22ABB75A99A2Q34336456-CEBA96D0-18E7-4803-9C21-70E6125E0FE6Q34437229-98A8E4B4-0865-4FBB-A7BB-18AB88EC5657Q34596336-6FEF4F70-F6FD-4007-A004-7830E2BCF638Q34955582-26EB0DCA-D0CB-44F2-9064-E2DC987CA835Q34994417-86BD4EC8-D95D-4A71-8018-6516BC44F814Q35106776-9558AFC8-D960-473A-B47B-68355068E8E8Q35592264-598FA829-EA28-477F-A98F-367589FBA9FCQ35607925-005DCF23-34A7-4261-85C0-7ED77EBCFC89Q35763406-E2C56A42-EB70-41D7-8510-36F3E17AE13BQ35941403-D771F8B0-2C67-4805-BA4F-D29A72E548B6Q36105647-6302BF05-4828-4E82-A8AC-494978A7A042Q36110885-BC5BF907-F746-4F55-9778-C80CE4A2D22BQ36120398-AE0CC897-CACF-42FD-A150-63D54A4D62B9Q36171772-36AC5D88-AC64-4065-AE79-342C20DF1CB8Q36172505-A802AFFE-DE1D-4328-A777-FAB5198EECA7Q36290841-7B93C2F1-EB46-4989-A351-CFFB0803B13DQ36299428-3457065A-F39B-410A-8584-82CBE21D3CFFQ36761826-CE2AF6F9-BC1E-4208-A852-791D46C9C6A5Q37023206-4A4FE44D-2C36-437B-A87F-C896D6778CDBQ37036511-F5D10CB0-5B3F-4C97-901A-C2BFD975E618Q37053617-411B1832-1B73-4FB6-9CC3-4139A389DA05Q37358693-84F3BC59-AEFD-47AA-9B17-9D76194F5233Q37600495-E4FE0BF5-2235-4E73-90AB-3B47F4D00DB7Q37712983-65B3F864-79FA-4A5E-A6C6-B37059CD057AQ38078878-837F92BF-E1DB-4FCB-BE3A-3F33963BE931Q38097120-3D6ECB6E-196A-4E08-933E-4336ADA28C98Q38100749-38CC99FC-C8A5-4D9E-84AE-A20573F75DBFQ38192023-10C8EAC7-2AED-4656-BE79-FAD3620FBD1EQ38232199-CC0BBBA9-02BD-4A55-9A01-8B70F4300D23Q38246001-8A72A207-5171-4DB1-A247-A2754B461757Q38247400-3C49DEFF-6738-40F6-A127-B41644FEC5E7Q38252561-D6165365-8D52-459B-9887-3D7EA24ECE0C
P2860
Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Incidence of and risk factors ...... large academic health system.
@en
Incidence of and risk factors ...... large academic health system.
@nl
type
label
Incidence of and risk factors ...... large academic health system.
@en
Incidence of and risk factors ...... large academic health system.
@nl
prefLabel
Incidence of and risk factors ...... large academic health system.
@en
Incidence of and risk factors ...... large academic health system.
@nl
P2093
P2860
P356
P1476
Incidence of and risk factors ...... large academic health system.
@en
P2093
Dror Marchaim
Jason M Pogue
Jing J Zhao
Keith S Kaye
Paul Lephart
Victoria Yee
P2860
P304
P356
10.1093/CID/CIR611
P407
P50
P577
2011-09-07T00:00:00Z